You are here

Article info

Article menu
Therapeutics
Original article
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease

Authors

  1. Correspondence to Professor Dominique P Germain, Division of Medical Genetics, University of Versailles—St Quentin en Yvelines, Hopital Raymond Poincare (AP-HP), 92380 Garches, France; dominique.germain{at}rpc.aphp.fr
View Full Text

Citation

Germain DP, Charrow J, Desnick RJ, et al
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
Journal of Medical Genetics 2015;52:353-358.

Publication history

  • Received September 29, 2014
  • Revised January 31, 2015
  • Accepted February 11, 2015
  • First published March 20, 2015.
Online issue publication 
September 20, 2018

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/